Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells--identification of a novel androgen response element
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Cyclin D1 gene (CCND1) is a critical mitogen-regulated cell-cycle control element whose transcriptional modulation plays a crucial role in breast cancer growth and progression. Here we demonstrate that the non-aromatizable androgen 5-α-dihydrotestosterone (DHT) inhibits endogenous cyclin D1 expression, as evidenced by reduction of cyclin D1 mRNA and protein levels, and decrease of CCND1-promoter activity, in MCF-7 cells. The DHT-dependent inhibition of CCND1 gene activity requires the involvement and the integrity of the androgen receptor (AR) DNA-binding domain. Site directed mutagenesis, DNA affinity precipitation assay, electrophoretic mobility shift assay and chromatin immunoprecipitation analyses indicate that this inhibitory effect is ligand dependent and it is mediated by direct binding of AR to an androgen response element (CCND1-ARE) located at -570 to -556-bp upstream of the transcription start site, in the cyclin D1 proximal promoter. Moreover, AR-mediated repression of the CCND1 involves the recruitment of the atypical orphan nuclear receptor DAX1 as a component of a multiprotein repressor complex also embracing the participation of Histone Deacetylase 1. In conclusion, identification of the CCND1-ARE allows defining cyclin D1 as a specific androgen target gene in breast and might contribute to explain the molecular basis of the inhibitory role of androgens on breast cancer cells proliferation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Specific protection against breast cancers by cyclin D1 ablation
Yu, Q., Geng, Y., & Sicinski, P. (2001) · Nature · doi:10.1038/35082500 · Cited by 934 · cited 1×
“The biologically relevant role of cyclin D1 in breast tumourigenesis has been evidenced by several findings: mammary gland-targeted cyclin D1 over-expression resulted in mammary hyperplasia and adenocarcinoma in transgenic mice (9); cyclin D1 antisense blocked ErbB2-induced mammary tumour growth in vivo (10), and cycl…”
BackgroundLabrie, F., Luu-The, V., Labrie, C., Bélanger, A., Simard, J., Lin, S.-X., & Pelletier, G. (2003) · Endocrine Reviews · doi:10.1210/er.2001-0031 · Cited by 544 · cited 1×
“in congenital adrenal hyperplasia) suppresses breast development (20), while mice lacking a functional androgen receptor (AR) display defective mammary gland development and morphogenesis (21).”
BackgroundZhou, J., Ng, S., Adesanya-Famuiya, O., Anderson, K., & Bondy, C. A. (2000) · The FASEB Journal · doi:10.1096/fj.99-0863com · Cited by 193 · cited 1×
“cells, (26), while over-expression of the AR in MCF-7 cells markedly decreases oestrogen receptor a (ERa) transcriptional activity (27–28).”
BackgroundVerrijdt, G. (2003) · Molecular Genetics and Metabolism · doi:10.1016/s1096-7192(03)00003-9 · Cited by 148
Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer.
TORMEY, D. C., LIPPMAN, M. E., EDWARDS, B. K., & CASSIDY, J. G. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-2-139 · Cited by 128
Role of the androgen receptor in human breast cancer.
Birrell, S. N., Hall, R. E., & Tilley, W. D. (1998) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1018730519839 · Cited by 124
Cited by
Montalto, F. I., & De Amicis, F. (2020) · Cells · doi:10.3390/cells9122648 · Cited by 496
Minireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?
Hickey, T. E., Robinson, J. L. L., Carroll, J. S., & Tilley, W. D. (2012) · Molecular Endocrinology · doi:10.1210/me.2012-1107 · Cited by 289
“Another study by this group has shown that direct down-regulation of the cyclin D1 gene is involved in the antiproliferative effect of androgen signaling in MCF-7 cells, mediated via interaction with an orphan nuclear receptor called DAX1 (111).”
BackgroundEvidence of androgen action in endometrial and ovarian cancers
Gibson, D. A., Simitsidellis, I., Collins, F., & Saunders, P. T. K. (2014) · Endocrine-Related Cancer · doi:10.1530/erc-13-0551 · Cited by 73
“Interestingly, cyclin D1 (CCND1), a protein which is important in regulating the cell cycle is reported to be AR regulated (Lanzino et al. 2010).”
BackgroundWang, Y., He, X., Yu, Q., & Eng, C. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt077 · Cited by 57
Sirianni, R., Capparelli, C., Chimento, A., Panza, S., Catalano, S., Lanzino, M., Pezzi, V., & Andò, S. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.08.002 · Cited by 25
“Androgen-dependent AR activation has been extensively correlated with inhibition of basal and estradiol-induced breast cancer cell proliferation (Lanzino et al., 2010; Peters et al., 2009).”
Self-citation
Metadata
- Authors
- Lanzino, M., Sisci, D., Morelli, C., Garofalo, C., Catalano, S., Casaburi, I., Capparelli, C., Giordano, C., Giordano, F., Maggiolini, M., & Ando, S.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-04-26
- Volume
- 38
- Issue
- 16
- Pages
- 5351-5365
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- OpenAlex
- W2082486840
- Cited by
- 90
- References
- 6
- FWCI
- 3.86
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells--identification of a novel androgen response element. https://app.cochat.ai/papers/10.1093/nar/gkq278
- The paper
- Lanzino, M., Sisci, D., Morelli, C., Garofalo, C., Catalano, S., Casaburi, I., Capparelli, C., Giordano, C., Giordano, F., Maggiolini, M., & Ando, S. (2010). Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells--identification of a novel androgen response element. Nucleic Acids Research. https://doi.org/10.1093/nar/gkq278
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.